Infusion Magazine |
BIOTECH THERAPIES
Counce JB. Amgen: Science-based, patient-driven, provider-friendly;8(5):29-31.
Deitz-Lovett K. Managing chemotherapy-induced anemia: Supportive care plan for home infusion therapy. 2006.12(6):S1-S8.
Lima HA, Manning JO, Peters ME. Gaucher disease and enzyme replacement therapy. 1996;2(7):39-44.
Lima HA. Cystic fibrosis: Advances in treatment. 1999;5(6):27-30.
Lima H. Looking down the pipeline: A biotech market update. 2000;7(1):14-9.
McCloskey WW, Stofko, JP. Human growth hormone therapy: An overview. 1996;2(5):40-44.
McCloskey WW, Stofko JP. Interferons in clinical practice: An update. 1996;3(3):31-37.
McKinnon B. Disease management for biotech drugs. 1996;2(9):31-39.
McKinnon BT. Biotechnology approaches the millennium-And managed care strategies keep pace. 1999;5(6):18-21.
McKinnon BT. Growth hormone: It's not just for kids. 1999;5(6):32-36.
McKinnon BT. Synagis®: A clinical overview. 2000;7(1):26-32.
Mohler L. Looking down the pipeline: New drugs and biologicals for 2006. 2006:12(1):21-3.
Rizk M. Hemophilia and biotechnology: An update. 1999;5(6):23-26.
Schumann K. Healthier babies: A valuable outcome. 2000;7(1):20-5.
Zimay D and Erickson K. Pediatric patients with immune disorders: Utilization patterns and clinical outcomes. 1999;5(8):29-33.